AmDerma Pharma, Oculus Innovative (OCLS) Enter Microcyn Technology Development Agreement

AmDerma Pharmaceuticals, LLC, a privately owned company (and parent company of Quinnova Pharmaceuticals, Inc.) and Oculus Innovative Sciences (Nasdaq: OCLS), today announced the execution of an agreement to develop and commercialize Oculus' novel proprietary Microcyn Technology drug compounds for major dermatological conditions, including acne. The exclusive agreement includes licensing of the dermatology compounds in the United States and India, with a first right of refusal for all member states of the European Union, Canada, Brazil and Japan. Oculus retains all rights for the rest of the world.

Under the terms of the agreement, Oculus received an undisclosed upfront payment, and will receive multiple clinically based payments upon achievement of several development and regulatory milestones for both acne and secondary indications, as well as future escalating double-digit royalties on net sales of products. The agreement also memorializes the intent for future joint development of additional dermatological products and indications.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• TrueBlue's (TBI) PeopleScout Announces Appointments to its Executive Team
• Arvinas Inc. (ARVN) Appoints Randy Teel as Chief Business Officer